Clinical Trials Logo
  1. Home
  2. Obesity
  3. NCT05975541
  4. Details
NCT05975541 Clinical Trial

Susceptibility to Infectious Diseases in Obesity

Obesity Clinical Trial

— SIDERALE  

Official title:
Susceptibility to Infectious Diseases in Obesity: an Endocrine, Translational, Sociological Evaluation

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05975541
Other study ID # CE277/2022
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2023
Est. completion date October 1, 2025

Study information
Verified date January 2024
Source Azienda Ospedaliero Universitaria Maggiore della Carita
Contact Flavia Prodam, Prof.MD
Phone +39 0321 660 693
Email flavia.prodam@med.uniupo.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The role of intestinal microbiota is becoming ever more important in the context of obesity, type II diabetes (T2D), and infectious disorders as represented by the emerging discipline "therapeutic microbiology". The gut microbiota is strictly interconnected with obesity and T2D playing also an important role in immune system regulation. Obesity and diabetes can lead to chronic inflammation, which results in the secretion of pro-inflammatory cytokines like IL-6, IL-1, and TNF-alpha, causing immune system alteration which predisposes patients with obesity and T2D to chronic infections. Therefore, the principal aim of the study is to investigate changes in gut microbiota composition between patients with chronic infections or not, so as to attribute to specific phyla the formation of the infections in these patients.

Description:

Obesity is nowadays a relevant public issue, with more than 650 million people affected worldwide. By definition, obesity is characterized by excessive calorie intake and lowering energy expenditure favored today by the increased sedentary lifestyle and junk food availability. Obesity represents a risk factor for cardiovascular diseases, neoplasm, and first of all type II diabetes. Nonetheless, obesity increases susceptibility to infectious disorders such as urinary tract infections, periodontitis, herpes virus infection, and also Covid-19. During the pandemic, obese patients were interested in the severe form of Covid-19 and also they presented less response to the vaccine. Because of insulin resistance and chronic inflammation, typical of obese patients, T2D is a classical comorbidity presented by these individuals. Together these two pathologies lead to immune system deregulation and a high predisposition to secondary infections. A third player is the gut microbiota, recent discoveries demonstrated as intestinal microbiota is strictly interconnected with obesity and diabetes and with the circadian clock. Being the gut microbiota an important regulator of the immune system changes in gut microbiota composition induced by diet, obesity, and T2D can be reflected in the impairment of the immune system. The purpose of the present study is the investigation of the gut microbiota signature in patients presenting obesity and T2D with or without infectious diseases. The idea is the identification of microbiota composition about pathological, metabolomic, and socio-economic features. Obtained results from this study could be used for the identification of new therapeutic targets involved in the development of these pathologies.

Recruitment information / eligibility
Status Recruiting
Enrollment 80
Est. completion date October 1, 2025
Est. primary completion date February 25, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - age between 18-65 years - ability to understand the study protocol - obesity with BMI between 30-40 kg/m2 - affects by type II diabetes - presence/absence of chronic infections - the possibility of equality in the two groups (matched for sex, age, and therapies) Exclusion Criteria: - psychological conditions that reduced the ability the comprehension of the study protocol - subjects undergoing a diet-therapeutic regimen; - subjects with the possibility of developing diabetic foot in the successive months - patients with relapsing infections - pregnancy - bariatric surgery - oncological and hematological pathologies - Hypogonadism - severe immunodepression - vaccination in the last two weeks - Alcohol or drug abuse - antibiotic therapy

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Observational
No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.

Locations
Country Name City State
Italy Maggiore della Carità Hospital Novara

Sponsors (1)
Lead Sponsor Collaborator
Azienda Ospedaliero Universitaria Maggiore della Carita

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary Omic signature differences between group of case and group of control it is expected to find differences in the signature of the gut microbiota between patients with chronic infections and those not having infections Changes in microbiota composition between time 0 months (start point of the study) and 12 months (end point of the study)
Primary Immune system differences between group of case and group of control DIfferences among pro-inflammatory cytokines (IL-6, IL-1, IL-10, IL-17, IL-18, TNF-alpha) Changes in the level and type of pro-inflammatory cytokines between basal time, 0 months , 6 and 12 months (end of the study) in both case and control group
Primary Patient card for the evaluation of the pharmacological therapy Changes in pharmacological therapy for the treatment of diabetes, obesity, or concomitant infections due to aggravation or resolution of the pathology will be investigated through the use of a patient card. changes between time 0 months (basal time) and 12 months (end of the study)
Primary Identification of the oral microbiota collection of oral microbiota by swab both in the control group and in the case changes in oral microbiota between the two different groups at time 0 months, 6 months and 12 months
Primary Number of white blood cells Use of the leucocyte formula for evaluating the number of white blood cells (WBC) in the patient's blood in both case and group. changes in WBC biochemical levels between time 0 months, 6 months and 12 months in both case and control groups
Primary Blood cells count Evaluation of the blood cells with particular attention to the red blood cells in both control and case groups. changes in blood cells count between time 0 months, 6 months and 12 months in both case and control group
Primary Lipid profile identification Evaluation of the total cholesterol, LDL, and triglycerides through blood sample collection in both case and control groups. changes in lipid profile between time 0 months, 6 months and 12 months in both case and control group
Primary Uric acid concentration Evaluation of the levels of uric acid through blood sample collection in patients. changes in uric acid levels between time 0 months, 6 months and 12 months in both case and control group
Primary Evaluation of urine parameters Detection of the levels of microalbuminuria and creatinuria in patients of both group through urine collection and analysis. changes in microalbuminuria and creatinuria levels between time 0 months, 6 months and 12 months in both case and control group
Primary Concentration of vitamin D Detection of Vitamin D levels in patients, through blood sample collection. changes in vitamin D levels between time 0 months, 6 months and 12 months in both case and control group
Primary Detection of immunoglobulins Total immunoglobulins evaluation (IgE, IgA, IgD, IgG, IgM) in patients through blood sample collection. The analysis will be performed on both case and control groups. changes in immunoglobulins profile between time 0 months, 6 months and 12 months in both case and control group
Primary QPE index evaluation Evaluation of album, alpha-1 globulin, alpha-2 globulin, beta-globulin, and gamma-globulin through protein electrophoresis (QPE) in both case and control groups. Changes in QPE index level between time 0 months, 6 months and 12 months in both case and control group
Primary Concentration of electrolyte levels Detection of phosphorus and calcium levels in patients, through blood sample collection of both case and control groups. Changes in the electrolyte levels between time 0 months, 6 months and 12 months in both case and control group
Primary Detection of haptoglobins level Evaluation of the haptoglobins levels in patients through blood sample collection. Changes in haptoglobins levels between time 0 months, 6 months and 12 months in both case and control group
Primary Fecal calprotectin levels identification Detection of fecal calprotectin levels in stool samples collected from patients in both groups. Changes in fecal calprotectin levels between time 0 months, 6 months and 12 months in both case and control group
Secondary body weight monitoring observation of body weight differences in both case and control groups. changes between time 0 months and time 12 months
Secondary BMI classification individuals will be obese and therefore classify based on BMI, during the study this classification could be change change in BMI classification between time 0 months (basal) and 12 months (end of the study)
Secondary evaluation of waist and hip circumference changes in waist and hip circumference in both groups changes between time 0 months. 6 months and 12 months
Secondary assessment of dietary habits identification of dietary habits in control groups and in the case group. Detection of the differences in the dietary habits between the two groups through the use of some specific and validated questionnaires (24h recall and Predimed).
A 24-hour dietary recall (24HR) questionnaire to provides information about the consumption of food groups of particular interest, such as the total intake of fruits, vegetables, or added sugars.
Predimed is a questionnaire based on adherence to the Mediterranean Diet. There is a final score that allows to identify those patients that follow this kind of nutritional regimen. Each question (if true for Mediterranean Diet) gives 1 point; the final score is structured as follows:
=5 Low adherence 6 - 9= medium adherence >10 good adherence		 changes in dietary habits between time 0 and time 12 months.
Secondary assessment of the circadian rhythm trough MEQ questionnaire Detection of the circadian rhythm through the Morningness Eveningness Questionnaire (MEQ) in patients of both control and case groups.
MEQ is a self-assessment questionnaire developed to measure whether a person's circadian rhythm (biological clock) produces peak alertness in the morning, in the evening, or in between.
The standard MEQ consists of 19 multiple-choice questions, each having four or five response options.
Responses to the questions are combined to form a composite score that indicates the degree to which the respondent favors morning versus evening. The score is in a range between 16 and 86. If the score is lower or equal to 41 the patient is classified as an "evening" type; equal to or higher than 59, the patient is a "morning" type; between 42 and 58 is a "middle" phenotype.		 changes in circadian rhythm between time 0 months, 6 months and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2

External Links